![](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ih_240717_purpose_1_hiv_800x450.jpg)
PURPOSE 1 Lenacapavir Results 'Highly Anticipated'
The HIV community will soon get to look at data from the PURPOSE 1 clinical trial of twice-yearly lenacapavir for preexposure prophylaxis after interim results showed it was 100% effective in preventing infection. Linda-Gail Bekker, MBChB, director of the …